Evidence map›Paper›PMID 42068355›Full record

ArticleVirchows Archiv : an international journal of pathology2026

Aberrant GATA3 reactivity in a clear cell renal cell carcinoma with clear cell papillary renal cell tumor-like features: a case report.

Miruna C Popescu, Mahmut Akgul, Sean R Williamson, Ankur R Sangoi

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Miruna C PopescuInstitute of Pathology, RKH Hospital, Ludwigsburg, Germany.ORCID http://orcid.org/0009-0006-5899-4556
Mahmut AkgulDepartment of Pathology, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0929-0940
Sean R WilliamsonDepartment of Pathology, Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-3898-1460
Ankur R SangoiDepartment of Pathology, Stanford Medical Center, Stanford Hospital, 300 Pasteur Drive, Stanford, CA, 94305, USA. asangoi@stanford.edu.ORCID http://orcid.org/0000-0003-0874-8964

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clear cell papillary renal cell tumor (CCPRCT) has been reclassified from "carcinoma" to "tumor" in the latest World Health Organization (WHO) Classification in 2022 to better reflect its excellent outcome. Therefore, its distinction from its closest mimic, clear cell renal cell carcinoma (CCRCC), is now more clinically relevant than ever. The well-documented occurrence of tumors with significant overlapping morphologic and immunohistochemical features between CCPRCT and CCRCC has sparked a search for additional immunohistochemical markers that may aid in this distinction. Based on the putative distal nephron origin of CCPRCT, GATA binding protein 3 (GATA3) has been proposed as a sensitive and specific marker for this diagnosis, with only exceptional cases of CCRCC reported to show GATA3 reactivity. To the best of our knowledge, this is the first report of a molecularly-confirmed, low-stage, low-grade CCRCC showing overlapping histology with CCPRCT and an exceptional CCPRCT-like immunohistochemical profile, including diffuse nuclear expression of GATA3.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellGATA3 Transcription FactorKidney NeoplasmsCarcinoma, PapillaryHumansImmunohistochemistryMaleBiomarkers, TumorGATA3 protein, humanGATA3 Transcription FactorAberrantBorderline featuresClear cell papillary renal cell tumorClear cell renal cell carcinomaGATA3Overlap

Identifiers

PMID42068355

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.